Special Issue "Targets, Tracers and Translation, Part 2 - New Horizons in Radiopharmaceutical Development"
Deadline for manuscript submissions: 31 December 2021.
2. Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Germany
Interests: radiopharmaceutical sciences; PET isotope production methods; PET tracer development; small molecules; antibodies and fragments; imaging of hypoxia/inflammation/infectious diseases; preclinical evaluation and translation into clinical application
Special Issues and Collections in MDPI journals
Dear Radiopharmaceutical Community,
Two years have passed since our first Special Issue on “Targets, Tracers and Translation”. In the meantime, the journal was indexed by SCIE with an impressive IF of 4.286 for 2019. As the first Special Issue was a remarkable success, it has now been decided that the right time has arrived to open a Part 2.
Radiopharmaceutical Sciences have impressively demonstrated their innovative power over the last few years to move nuclear medicine forward. The question of what comes beyond [18F]FDG can definitely be put to the archives. The global story of success of PSMA PET imaging and endoradiotherapy is the best example, and more targets of interest have been defined and tracer developments for a highly specific imaging have shown promising results. Imaging of, for example, senescence, cellular stress or specific receptors (e.g., CXCR4) in oncology offers new perspectives for therapy planning and control. Immunoimaging of therapy responses of tumors (e.g., CD4, CD8 or CD69 activation) is another highlight in the attempts at improving individual patient management. Of course, recent developments are not limited to oncology—there is also significant progress in the imaging of infectious diseases or in neurosciences, here especially to specifically image beta-amyloid plaques, tau or alpha-synuclein proteins or TSPO in neuro degeneration.
Additionally, successful attempts to broaden the availability of, so far, less common radionuclides for imaging and therapy have to be mentioned. The possibilities of production of extremely high amounts of [18F]fluoride in new target systems for cyclotrons, the availability of gallium-68 from the cyclotron, overcoming limitations of the generator, and also a wider availability of other cyclotron produced radionuclides such as scandium-43 and -44, copper-61 or copper-64, and zirconium-89 with longer half-lives open new perspectives in tracer design. For therapy, in addition to the currently widely used lutetium-177, alpha emitters such as actinium-225 have become available and broaden the spectra.
Recently, total-body PET scanners have started to break into the market. This will help to reduce radiation doses given to patients with longer-lived isotopes and facilitate their usage. At the same time, total-body PET offers a new entrance into radiopharmaceutical research on novel classes of radiotracers.
With this Special Issue, we want to illustrate and highlight the variety in recent radiopharmaceutical developments and the new horizons that are opened toward a broad spectrum of applications. The final goal of these developments, of course, the successful translation into the clinics and into nuclear medicine practice, should always be the focus.
We cordially invite you to participate in this Special Issue, “Targets, Tracers and Translation, Part 2—New Horizons in Radiopharmaceutical Development” and are excited to receive your latest successful results and share them with the community. In addition to original works, reviews are very welcome, as well.
PD Dr. Gerald Reischl
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- novel radiopharmaceuticals
- molecular imaging